| 查看: 1145 | 回复: 6 | ||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | ||
[求助]
药物晶型 已有3人参与
|
||
| 在多晶型抗癌药中，有没有哪种药物的某一种晶型有药效，而其他晶型没有药效，求教几种抗癌药的名称？ |
回复此楼» 猜你喜欢
厉娜
已经有5人回复
-
售SCI一区T0P文章，我:8.O.55.1.O54,科目全,可伽急
已经有12人回复
-
售SCI-T0P文章，我:8O.5.5.1.O.54,科目齐全,可+急
已经有15人回复
-
售SCI文章，我:8O.5.5.1O.54,科目全,可十急
已经有14人回复
-
售SCI一区T0P文章，我:8O.55.1.O.54,科目全,可伽急
已经有16人回复
-
售SCI文章，我:8O.5.5.1O.54,科目全,可十急
已经有15人回复
-
售SCI一区文章，我:8O5.5.1.O5.4,科目全,可伽急
已经有10人回复
-
售SCI一区T0P文章，我:8O.55.1.O.54,科目全,可伽急
已经有12人回复
-
售SCI一区文章，我:8.O.55.1.O.54,科目齐全,可伽急
已经有8人回复
-
售SCI一区T0P文章，我:8.O.55.1.O.54,科目齐全,可+急
已经有8人回复
wachina
至尊木虫 (知名作家)
- 应助: 228 (大学生)
- 贵宾: 0.03
- 金币: 15996.8
- 散金: 2
- 红花: 13
- 帖子: 5306
- 在线: 683.4小时
- 虫号: 770872
- 注册: 2009-05-15
- 性别: GG
- 专业: 合成药物化学
4楼2014-11-17 10:14:25
2楼2014-11-17 09:41:56
3楼2014-11-17 10:06:09
xujun9998
版主 (著名写手)
- 应助: 352 (硕士)
- 贵宾: 0.964
- 金币: 24443.2
- 散金: 2050
- 红花: 34
- 帖子: 2033
- 在线: 765.8小时
- 虫号: 121124
- 注册: 2005-12-03
- 性别: GG
- 专业: 有机合成
- 管辖: 有机资源
【答案】应助回帖
感谢参与，应助指数 +1
|
Title: Imatinib 格列卫（甲磺酸伊马替尼胶囊） CAS Registry Number: 152459-95-5 CAS Name: 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Additional Names: N-[5-[4-(4-methylpiperazinomethyl)benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine Molecular Formula: C29H31N7O Molecular Weight: 493.60 Percent Composition: C 70.57%, H 6.33%, N 19.86%, O 3.24% Literature References: Tyrosine kinase inhibitor; highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). Also shown to inhibit the transmembrane receptor KIT and platelet-derived growth factor (PDGF) receptors. Prepn: J. Zimmermann, EP 564409; idem, US 5521184 (1993, 1996 both to Ciba-Geigy); idem et al., Bioorg. Med. Chem. Lett. 7, 187 (1997). Structural mechanism of ABL specificity: T. Schindler et al., Science 289, 1938 (2000). Activity vs KIT and PDGF receptor kinases: E. Buchdunger et al., J. Pharmacol. Exp. Ther. 295, 139 (2000). Clinical trial in CML: H. Kantarjian et al., N. Engl. J. Med. 346, 645 (2002); in gastrointestinal stromal tumors related to KIT: G. D. Demetri et al., ibid. 347, 472 (2002). Review of clinical experience: D. G. Savage, K. H. Antman, ibid. 346, 683-693 (2002); and pharmacology: V. K. Pindolia et al., Pharmacotherapy 22, 1249-1265 (2002); and development of therapeutic target: B. J. Druker, Adv. Cancer Res. 91, 1-30 (2004). Properties: mp 211-213°. pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52. Melting point: mp 211-213° pKa: pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52 Derivative Type: Methanesulfonate CAS Registry Number: 220127-57-1 Manufacturers' Codes: STI-571; CGP-57148B Trademarks: Gleevec (Novartis); Glivec (Novartis) Molecular Formula: C29H31N7O.CH3SO3H Molecular Weight: 589.71 Percent Composition: C 61.10%, H 5.98%, N 16.63%, O 10.85%, S 5.44% Literature References: Prepn of crystalline form: J. Zimmermann et al., WO 9903854 (1999 to Novartis). Properties: Occurs in 2 crystalline modifications. a-form, begins to melt at 226°; b-form, mp 217°. Lipophilic at pH 7.4. Soly in water: >100 g/l (pH 4.2); 49 mg/l (pH 7.4). Melting point: mp 217° 结合上述内容并根据专利US6894051，也就是WO 9903854专利中的内容可知，本品的晶型诺华的格列卫（甲磺酸伊马替尼胶囊）所使用原料的晶型是β型。 |
5楼2014-11-17 11:24:51
